Immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells.
Rheumatoid arthritis is a chronic disorder for which there is no known cure. Concentrating on specific elements of the abnormal immune response that characterizes the disease, scientists are reaching into biotechnology's bag of tricks to develop immunotherapeutic techniques. This paper will present some advances in the immunotherapy of rheumatoid arthritis targeting inflammatory cytokines and autoreactive T cells.
Chen
Guangjie
G
Department of Immunology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, People's Republic of China. guangjie_chen@163.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015703:Antigens, CD / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000276:immunology* / Q000628:therapy*; D060908:CTLA-4 Antigen; D024043:Collagen Type II / Q000627:therapeutic use; D016207:Cytokines / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007167:Immunotherapy; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000637:transplantation
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D024043:Collagen Type II; D016207:Cytokines